台灣臨床試驗主持人資料庫|TPIDB

2017-06-01 - 2019-12-31

Phase II/III

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy

Condition/Disease

Advanced or Metastatic Biliary Tract Cancer
Test Drug

Varlitinib

Participate Sites
7Sites

Terminated5Sites

白禮源

China Medical University Hospital-Taipei

未分科

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-02-01 - 2016-12-31

Phase III

A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate to Very Severe COPD, Compared with Placeb

Condition/Disease

COPD
Test Drug

Glycopyrronium and Fomoterol Fumarate Inhalation Aerosol

Participate Sites
6Sites

Terminated5Sites

杭良文

China Medical University Hospital-Taipei

未分科

2017-05-01 - 2025-12-31

Others

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

Condition/Disease

Nonalcoholic Steatohepatitis
Test Drug

CVC /150mg tablet

Participate Sites
13Sites

Not yet recruiting9Sites

Recruiting1Sites

Terminated1Sites

彭成元

China Medical University Hospital-Taipei

未分科

2016-01-01 - 2019-12-31

Phase I

A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

Condition/Disease

ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)
Test Drug

LDK378

Participate Sites
6Sites

Terminated5Sites

夏德椿

China Medical University Hospital-Taipei

未分科

2016-02-22 - 2022-12-22

Phase II

A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease

Condition/Disease

Non-small Cell Lung Cancer
Test Drug

INC280

Participate Sites
6Sites

Recruiting5Sites

夏德椿

China Medical University Hospital-Taipei

未分科

張文震

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-03-01 - 2017-12-31

Phase II

A double blind, randomized, placebo-controlled study to evaluate safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis

Condition/Disease

active dermatomyositis
Test Drug

BAF312

Participate Sites
3Sites

Terminated1Sites

Study ended1Sites

藍忠亮

China Medical University Hospital-Taipei

未分科

2019-02-28 - 2023-04-30

Phase II

A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Condition/Disease

Breast cancer
Test Drug

KISQALI

Participate Sites
9Sites

Recruiting8Sites

劉良智

China Medical University Hospital-Taipei

未分科

陳訓徹

Linkou Chang Gung Medical Foundation

2018-07-31 - 2021-05-04

Phase III

A Two-Year, Two-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KITE)

Condition/Disease

Diabetic Macular Edema (KITE)
Test Drug

RTH258

Participate Sites
4Sites

Terminated3Sites

林純如

China Medical University Hospital-Taipei

未分科

2018-08-18 - 2022-07-11

Phase III

FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1

Condition/Disease

Untreated Advanced Gastric and Gastroesophageal Cancer
Test Drug

FPA144

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated4Sites

白禮源

China Medical University Hospital-Taipei

未分科

2015-09-01 - 2017-04-04

Phase III

A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 Diabetes Mellitus (EASE2)

Condition/Disease

Type 1 Diabetes Mellitus
Test Drug

Jardiance®

Participate Sites
8Sites

Terminated7Sites

陳清助

China Medical University Hospital-Taipei

未分科

Search Result

List